• Approved formulations include:
  • 10mg, 25mg, 50mg, and 100mg capsules;
  • 100mg in 1ml sugar free oral solution (oily).
  • Should be prescribed by brand for transplant indications   
• For Transplant indications  unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes . 

• Approved for renal transplantation in children and adolescents in line with NICE.
• For Transplant indications  unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes . 

Approved tacrolimus formulations include:

• 500 microgram, 1mg & 5mg capsules (Prograf® & Adoport®).
• 1mg in 1ml oral suspension (unlicensed) - this replaces 0.5mg/ml oral
  suspension. 
• 5mg in 1 ml concentrate for preparing IV infusion - approved for renal transplantation in children and adolescents in line with NICE.
• 500microgram, 1mg, 3mg & 5mg MR capsules (Advagraf®) approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is also approved for use in patients who are currently prescribed Prograf®, and de novo patients should be prescribed Adoport®.
• 750microgram, 1 mg and 4 mg m/r tablets (Envarsus®)
  
  • approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus. 
• For Transplant indications  unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes . 

• 7.9mg capsules
• Approved with mycophenolate mofetil for treating lupus nephritis in adults in line with NICE and NHSe Specialised Commissioning Policy (SSC2540)
• Only available from:
  
  • North Cumbria University Hospital NHS Trust
  • South Tyneside and Sunderland NHS Foundation Trust
  • South Tees Hopsitals NHS Foundation Trust
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

• NETAG approved for aplastic anaemia in adults (unlicensed).

• Used in the management of transplant rejection.

• Approved for limited use in adult renal transplant patients with high risk of acute organ rejection.
• Approved for severe graft versus host disease post haematopoietic stem cell transplantation.
• Approved for induction therapy in renal transplantation in children and adolescents in with combinations that include ciclosporin in line with NICE.